4-(Boc-amino)-L-phenylalanine
Need Assistance?
  • US & Canada:
    +
  • UK: +

4-(Boc-amino)-L-phenylalanine

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Category
BOC-Amino Acids
Catalog number
BAT-007845
CAS number
74578-48-6
Molecular Formula
C14H20N2O4
Molecular Weight
280.32
4-(Boc-amino)-L-phenylalanine
IUPAC Name
(2S)-2-amino-3-[4-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]propanoic acid
Synonyms
L-Phe(4-NHBoc)-OH; H-PHE(4-NH-BOC)-OH; (2S)-2-AMINO-3-(4-[(TERT-BUTOXY)CARBONYLAMINO]PHENYL)PROPANOIC ACID; H-Phe(4-NHBoc)-OH; (S)-2-Amino-3-(4-((tert-butoxycarbonyl)amino)phenyl)propanoic acid; 4-(t-Butoxycarbonylamino)-L-phenylalanine
Appearance
Pale yellow solid
Purity
≥ 97% (HPLC)
Storage
Store at 2-8 °C
InChI
InChI=1S/C14H20N2O4/c1-14(2,3)20-13(19)16-10-6-4-9(5-7-10)8-11(15)12(17)18/h4-7,11H,8,15H2,1-3H3,(H,16,19)(H,17,18)/t11-/m0/s1
InChI Key
QRMNAMRCSPROFV-NSHDSACASA-N
Canonical SMILES
CC(C)(C)OC(=O)NC1=CC=C(C=C1)CC(C(=O)O)N
1. Diastereo- and enantioseparation of a N(α)-Boc amino acid with a zwitterionic quinine-based stationary phase: focus on the stereorecognition mechanism
Federica Ianni, Andrea Carotti, Maura Marinozzi, Gloria Marcelli, Alessandro Di Michele, Roccaldo Sardella, Wolfgang Lindner, Benedetto Natalini Anal Chim Acta. 2015 Jul 23;885:174-82. doi: 10.1016/j.aca.2015.06.001. Epub 2015 Jun 9.
A chiral chromatography method enabling the simultaneous diastereo- and enantioseparation of N(α)-Boc-N(4)-(hydroorotyl)-4-aminophenylalanine [Boc-Aph(Hor)-OH, 1] was optimized with a quinine-based zwitterionic stationary phase. The polar-ionic eluent system consisting of ACN:MeOH:water-49.7:49.7:0.6 (v/v/v) with formic acid (4.0mM) and diethylamine (2.5mM), allowed the successful separation of the four acid stereoisomers: αd,d-/d,l-1=1.08; αd,l-/l,d-1=1.08; αl,d-/l,l-1=1.40. According to the in-house developed synthetic procedure and the recorded electronic circular dichroism spectra, the following stereoisomeric elution order was readily established in the optimal chromatographic conditions: d,d-1
2. Noncovalent chiral domino effect on one-handed helix of nonapeptide containing a midpoint L-residue
Yoshihito Inai, Hisatoshi Komori, Akinori Takasu, Tadamichi Hirabayashi Biomacromolecules. 2003 Jan-Feb;4(1):122-8. doi: 10.1021/bm0256303.
We here clarify whether noncovalent chiral domino effect characterized by the terminal interaction of a helical peptide with a chiral small molecule can alter the helical stability of N-deprotected peptides containing an L-residue covalently incorporated into the inner position. Two nonapeptides consisting of the midpoint L-leucine (1) or L-phenylalanine (2) and the achiral helix-forming residues were employed. NMR and IR spectroscopy and energy calculation indicated that both peptides adopt a 3(10)-helical conformation in chloroform. They strongly preferred a right-handed screw sense because of the presence of the midpoint L-residue. These original right-handed screw senses were retained on addition of chiral Boc-amino acid, but their helical stabilities clearly depended on its added chirality. Here, Boc-L-amino acid stabilizes the original right-handed helix, whereas the corresponding Boc-D-amino acid tends to less stabilize or destabilize it. This tendency was not observed for the corresponding N-Boc-protected peptides 1 and 2, strongly suggesting that the N-terminal amino group is required for controlling the stabilization of the original right-handed helix. Therefore, noncovalent chiral domino effect in peptides 1 and 2 can contribute even to the helical stability of a chiral peptide prevailing one-handed helix strongly through the midpoint L-residue. In addition, the N-terminal moiety of a 3(10)-helical peptide was found to generate chiral discrimination in complexation process with racemic additives.
3. Appraisal of a glycopeptide cloaking strategy for a therapeutic oligopeptide: glycopeptide analogs of the renin inhibitor ditekiren
A W Harrison, J F Fisher, D M Guido, S J Couch, J A Lawson, D M Sutter, M V Williams, G L DeGraaf, J E Rogers, D T Pals Bioorg Med Chem. 1994 Dec;2(12):1339-61. doi: 10.1016/s0968-0896(00)82086-6.
Among the limitations to the practical therapeutic oligopeptide are low oral availability, indifferent aqueous solubility, and an astonishing efficient sequestration and biliary elimination by a multi-capacity liver transporter. Given the purposed use of N- and O- linked saccharides as functional appendages of eukaryotic peptides and proteins, a strategy of glycopeptide mimicry was examined for the oligopeptide renin inhibitor, ditekiren. The anticipation was that the saccharide would impart significant aqueous solubility, and might impact beneficially on the remaining two limitations. Execution of this approach was achieved by the removal of the (dimethylethoxy)carbonyl amino terminus of ditekiren, and its substitution by Boc-L-asparagine N-linked mono- and disaccharides. Potent hypotensive activity, as measured by a human renin-infused rat assay, is observed for virtually all of these structures (N-linked beta-pyranose D-N-acetyglucosaminyl, D-glucosaminyl, D-N-acetylgalactosaminyl, D-mannosyl, D-galactosyl, D-maltosyl, D-cellobiosyl, D-chitobiosyl, but not L-fucosyl). The basis for this dramatic improvement (relative to ditekiren in the same assay) is the diversion of the peptide clearance from rapid liver biliary clearance to slower urinary clearance (Fisher, J. F.; Harrison, A. W.; Wilkinson, K. F.; Rush, B. R.; Ruwart, M. J. J. Med. Chem. 1991, 34, 3140). Guided by the human renin-infused rat hypertension assay, an evaluation of the linker-saccharide pairing was made. Loss of hypotensive activity is observed upon substitution of the Boc-L-asn by Boc-D-asn, and by removal of the Boc amino terminus of the glycopeptide. Potent hypotensive activity is preserved by replacement of the Boc-L-asn linker by succinate, malate, tartrate, and adipate linkers. With the longer adipate spacer, attachment of the saccharide to the P-3 phenylalanine--with omission of the P-4 proline--retains activity. These data suggest value to the glycopeptide guise for preserving the in vivo activity, and for the beneficial manipulation of pharmacodynamics, of this renin inhibitory oligopeptide. This strategy may have general applicability.
Online Inquiry
Verification code
Inquiry Basket